Please note: The information displayed on this page might be outdated.
Arvelle Therapeutics: Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital and KB Investments.
Phase III, Phase l or ll
Central Nervous System, Rare Disease
100MM - 500MM
Company Participants at European Biotech Investor Day 2020
- Mark Altmeyer, CEO